Novo Nordisk A/S Common Stock (NVO)

NOVO-NORDISK (NYSE:NVO) is a strong growth stock with solid fundamentals and a promising technical setup, offering potential for a breakout.

A consumer goods company hit 40% yearly revenue growth. In this environment?

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals.

The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline.

Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

The deal is worth up to $2.2 billion, including more than $200 million in upfront and near-term payments.

Septerna CEO Jeffrey Finer said that the collaboration allows the company to create multiple oral medicines and provides the operational flexibility and resources to advance its portfolio of other GPCR-targeted programmes.

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting its near-term impact on pharma stocks.

Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us.

Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders.

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Eli Lilly’s Zepbound led to 47% greater weight loss than Wegovy in a 72-week trial, yet retail sentiment turned bearish on Stocktwits amid heightened scrutiny on drug pricing following Trump’s vow to slash U.S. prescription costs by up to 80%.

Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.

With water scarcity, AI acceleration, and GLP-1 drugs reshaping demand, deal professionals are sprinting to adapt.

Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month.